Who makes Pre-transfection F17?

Pre-transfection F17 is developed by U.S. Army Medical Research and Development Command.

What development phase is Pre-transfection F17 in?

Pre-transfection F17 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Pre-transfection F17

U.S. Army Medical Research and Development Command · Phase 2 active Biologic

At a glance

Generic name	Pre-transfection F17
Sponsor	U.S. Army Medical Research and Development Command
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults (PHASE2)
A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pre-transfection F17 CI brief — competitive landscape report
Pre-transfection F17 updates RSS · CI watch RSS
U.S. Army Medical Research and Development Command portfolio CI